 - Ongoing androgen deprivation therapy ADT with a luteinizing hormone-releasing hormone LHRH agonist or antagonist at a stable dose and schedule within 4 weeks of initiation of investigational medicinal product IMP, or bilateral orchiectomy i.e., surgical or medical castration; 